ResMed adds Becton Dickinson CFO Christopher DelOrefice to board, effective August 15
ResMed expanded its board of directors to 11 and appointed Christopher DelOrefice, executive vice president and chief financial officer of Becton, Dickinson and Company, as a director on August 15, 2024. He will also serve on the board's audit committee and stand for re-election at the annual meeting on November 21, 2024. The filing reports no financial results or guidance changes tied to this appointment.
Key points
- Board expanded from its prior size to 11 directors; DelOrefice appointed August 15, 2024 at a regularly scheduled board meeting
- DelOrefice has been CFO of Becton, Dickinson and Company since September 2021 and previously held roles at Johnson & Johnson
- Appointed to the audit committee; term runs to the 2024 annual meeting on November 21, 2024
- He will receive director compensation on a pro rata basis and a standard indemnification agreement with ResMed
The filing
Written by AI on Nov 8, 2026, 1:30 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 16, 2024.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.